David F. McDermott - Publications, H-index & Citations

David F. McDermott

harvard medical school

109H指数

1.1K论文数

8.9W被引数

收录论文 161

发表时间

Is it time to reassess standard toxicity and patient reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)?是时候重新评估免疫检查点抑制剂（ICIs）辅助使用中的标准毒性和患者报告结果的方法了吗？

Annals of Oncology

IF65.4

2026-09-15

PREAI

E. Nally; J. Lyon; M. Regan; B. Rini; M. Voss; M.B. Atkins; T. Powles; D.F. McDermott

The clinical landscape of HIF2α inhibitors in oncology HIF2α 抑制剂在肿瘤学中的临床前景

Nature Reviews Clinical Oncology

IF82.2

2026-04-28

PREAI

Eddy Saad; Marc Machaalani; David F. McDermott; Toni K. Choueiri

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers 高级泌尿肿瘤共识会议（AUC3）2025：肾细胞癌和尿路肿瘤管理的专家共识

CA: A Cancer Journal for Clinicians

IF0

2025-12-13

OAAI

Rana R. McKay MD; Sumanta Pal MD; Wanling Xie MS; David Aggen MD, PhD; Laurence Albiges MD, PhD; Andrea Apolo MD; Michael B. Atkins MD; Rick Bangs MBA, PMP; Kathryn E. Beckermann MD, PhD; Joaquim Bellmunt MD, PhD; Stephanie A. Berg DO; Mehmet A. Bilen MD; David Braun MD, PhD; Maria I. Carlo MD; Jason Efstathiou MD, DPhil; Matthew Galsky MD; Petros Grivas MD, PhD; Shilpa Gupta MD; Naomi Haas MD; A. Ari Hakimi MD; Hans Hammers MD, PhD; Daniel Y. C. Heng MSC; Michelle Hirsch MD, PhD; Gopakumar Iyer MD; Eric Jonasch MD; Vadim S. Koshkin MD; Oleksandr Kryvenko MD; Bryan Lewis JD; Roger Li MD; Surena Matin MD; Benjamin Maughan MD, PharmD; David F. McDermott MD; Bradley McGregor MD; Joshua Meeks MD, PhD; Matthew Milowsky MD; Robert Motzer MD; Andrea Necchi MD; Dan Petrylak MD; Sima Porten MD, MPH; Thomas Powles MBBS, MRCP, MD; Brian Rini MD; Brian Shuch MD; Arlene Siefker-Radtke MD; Guru Sonpavde MD; S. Srikala Sridhar MD; Cristina Suarez MD, PhD; Chad Tang MD; Abhishek Tripathi MD; Michiel S. Van Der Heijden MD, PhD; Martin Voss MD; Wenxin Xu MD; Tian Zhang MD; Jonathan Rosenberg MD; Toni K. Choueiri MD

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma

JOURNAL OF IMMUNOLOGY

IF3.4

2025-11-01

PREAI

Wirth, Lena Vanessa; Hugaboom, Miya B.; Street, Kelly; Ruthen, Neil; Jegede, Opeyemi; Schindler, Nicholas; Shah, Valisha; Zaemes, Jacob; El Ahmar, Nourhan; Matar, Sayed; Savla, Varunika; Choueiri, Toni; Denize, Thomas; West, Destiny; Mcdermott, David F.; Plimack, Elizabeth R.; Sosman, Jeffrey; Haas, Naomi; Hurwitz, Michael E.; Hammers, Hans; Stein, Mark; Alter, Robert; Bilen, Mehmet; Signoretti, Sabina; Atkins, Michael B.; Wu, Catherine J.; Braun, David

CD163+Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial CD163+肿瘤相关巨噬细胞与转移性透明细胞肾细胞癌患者接受一线纳武利尤单抗治疗的临床结局：来自HCRN GU16-260试验的见解

ONCOLOGIST

IF4.2

2025-10-01

OAAI

Simsek, Berkay; Paul, Morgan A.; Xie, Wanling; El Ahmar, Nourhan; Matar, Sayed; Laimon, Yasmin Nabil; RobertiDe Oliveira, Gabriel; Mohanna, Razan; Delcea, Andrew; Choueri, Toni; Braun, David; Sun, Maxine; Haas, Naomi B.; Hammers, Hans J.; Bilen, Mehmet; Stein, Mark N.; Sosman, Jeffrey A.; Freeman, Gordon J.; Wu, Catherine; Mcdermott, David; Atkins, Michael B.; Signoretti, Sabina

Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)表征碳酸酐酶9和HIF-2α RNA在透明细胞肾细胞癌(ccRCC)中的表达

ONCOLOGIST

IF4.2

2025-10-01

OAAI

Chen, Yu-Wei; Nazari, Shayan; Elliott, Andrew; Kulkami, Ninad; Smith, Norm; Nawfal, Rashad; Barata, Pedro C.; Bagrodia, Aditya; Rose, Brent; McDermott, David; Signoretti, Sabina; Machaalani, Marc; Shiva, Shankar; Hofman, Michael; Agarwal, Neeraj; Pal, Sumanta; Choueri, Toni; Mckay, Rana

Immunotherapy response correlates in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes 转移性透明细胞肾细胞癌中循环游离表观基因组与免疫治疗效果的关联

ONCOLOGIST

IF4.2

2025-10-01

OAAI

El Hajj Chehade, Razane; Semaan, Karl; Zhang, Ze; Phillips, Noa; Canniff, John; Savignano, Hunter; Nawfal, Rashad; Eid, Marc; Grisham, Lexi; Prather, Rebecca; Beckermann, Katy; Vaishampayan, Ulka; Haas, Naomi; Hammers, Hans; McDermott, David; Wood, Lauren; Solley, Travis; Rini, Brian; Jonasch, Eric; Choueiri, Toni K.; Freedman, Matthew L.; Haake, Scott M.; Baca, Sylvan C.; Berchuck, Jacob E.

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes

ESMO OPEN

IF8.3

2025-02-01

PREAI

Xu, W.; Birch, G.; Meliki, A.; Moritz, V.; Bharadwaj, M.; Schindler, N. R.; Labaki, C.; Saliby, R. M.; Dinh, K.; Horst, J. T.; Sun, M.; Kashima, S.; Hugaboom, M.; Dighe, A.; Machaalani, M.; Lee, G. -s. m.; Hurwitz, M.; Mcgregor, B. A.; Hirsch, M. S.; Shukla, S. A.; Mcdermott, D. F.; Signoretti, S.; Romee, R.; Choueiri, T. K.; Braun, D. A.

Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial Nivolumab联合ipilimumab与舒尼替尼用于晚期肾细胞癌的一线治疗: CheckMate 214 III期试验的疗效和安全性的8年随访结果

ANNALS OF ONCOLOGY

IF65.4

2024-11-01

OAAI

Tannir, N. M.; Albiges, L.; Mcdermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Barthelemy, P.; Plimack, E. R.; Portat, C.; George, S.; Donskov, F.; Atkins, M. B.; Gurney, H.; Kollmannsberger, C. K.; Grimm, M. -o.; Barrios, C.; Tomita, Y.; Castellano, D.; Gruenwald, V.; Rini, B. I.; Jiang, R.; Desilva, H.; Fedorov, V.; Lee, C. -w.; Motzer, R. J.

Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study III期TIVO-3研究中，接受过免疫检查点抑制剂（CPI）治疗患者的更新总生存数据

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Zugman, M.; McDermott, D. F.; Escudier, B.; Hutson, T. E.; Porta, C. G.; Verzoni, E.; Atkins, M. B.; Rini, B. I.; Pal, S. K.

A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7 一项NPX887在已知表达HHLA2/B7-H7的实体瘤恶性病变受试者中的Ia/Ib期剂量递增/扩展研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Cheng, H.; Rivera, I. I. Rodriguez; McDermott, D. F.; Spira, A. I.; Ged, Y.; Liu, J.; Ji, Y.; Rausch, M.; Hashambhoy-Ramsay, Y.; Kis-Toth, K.; Gandhi, L.; Naing, A.

Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)I期LITESPARK-018研究：belzutifan在晚期经治透明细胞肾细胞癌（ccRCC）中的剂量递增研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Vaishampayan, U. N.; Saavedra, A. J. Zurita; Beckermann, K.; Chain, A.; Vickery, D.; Zhang, Y.; Perini, R.; McDermott, D. F.

Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)卡博替尼（Cabo）联合纳武利尤单抗（Nivo）和伊匹木单抗（Ipi）治疗不同组织学类型的晚期肾细胞癌（RCCdh）的II期研究更新结果

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

McGregor, B. A.; Paul, M.; Xie, W.; Xu, W.; Bilen, M. A.; Braun, D. A.; Berg, S.; Zhang, T.; McKay, R. R.; McDermott, D. F.; Hammers, H.; Choueiri, T. K.

Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma 肺免疫预后指数 (LIPI) 作为转移性肾细胞癌预后生物标志物的验证

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-06-01

PREAI

Carril-Ajuria, Lucia; Lavaud, Pernelle; Dalban, Cecile; Negrier, Sylvie; Gravis, Gwenaelle; Motzer, Robert J.; Chevreau, Christine; Tannir, Nizar M.; Oudard, Stephane; McDermott, David F.; Laguerre, Brigitte; Hammers, Hans J.; Barthelemy, Philippe; Plimack, Elizabeth R.; Borchiellini, Delphine; Gross-Goupil, Marine; Jiang, Ruiyun; Lee, Chung-Wei; de Silva, Heshani; Rini, Brian I.; Escudier, Bernard; Albiges, Laurence

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma 辅助Pembrolizumab治疗肾细胞癌的总生存率

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2024-04-18

PREAI

Choueiri, T. K.; Tomczak, P.; Park, S. H.; Venugopal, B.; Ferguson, T.; Symeonides, S. N.; Hajek, J.; Chang, Y-H; Lee, J-L; Sarwar, N.; Haas, N. B.; Gurney, H.; Sawrycki, P.; Mahave, M.; Gross-Goupil, M.; Zhang, T.; Burke, J. M.; Doshi, G.; Melichar, B.; Kopyltsov, E.; Alva, A.; Oudard, S.; Topart, D.; Hammers, H.; Kitamura, H.; McDermott, D. F.; Silva, A.; Winquist, E.; Cornell, J.; Elfiky, A.; Burgents, J. E.; Perini, R. F.; Powles, T.

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)nivolumab和savage nivolumab/ipilimumab治疗晚期透明细胞肾细胞癌的II期研究的无治疗生存结果 (HCRN GU16-260-Cohort A)

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2024-04-11

OAAI

Atkins, Michael B.; Jegede, Opeyemi A.; Haas, Naomi B.; Mcdermott, David F.; Bilen, Mehmet A.; Stein, Mark; Sosman, Jeffrey; Alter, Robert; Plimack, Elizabeth R.; Ornstein, Moshe C.; Hurwitz, Michael; Peace, David J.; Einstein, David; Catalano, Paul J.; Hammers, Hans; Regan, Meredith M.

Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Izar, Benjamin; Zamarin, Dmitriy; Spigel, David R.; Hoimes, Christopher J.; McDermott, David F.; Sehgal, Kartik; Najjar, Yana G.; Schoenfeld, Adam J.; Garon, Edward B.; Sullivan, Ryan J.; Henick, Brian S.; Leal, Ticiana A.; Hurwitz, Michael E.; McKay, Rana R.; Busby, Natalie; Mehta-Damani, Anita; Azrilevich, Alex; Tran, Tony; Rizvi, Naiyer; Oft, Martin; Spira, Alexander I.

High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Vemula, Sai Vikram; Xu, Wenxin; Wang, Yu; Liu, Xiaowen; de Somocurcio, Jorge Ruiz; McDermott, David; Li, Jun; Bhatt, Rupal; Lee, Chung-Wei; Simsek, Burcin; Gupta, Saurabh; Motzer, Robert

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-03-01

OAAI

Brahmer, Julie R.; Long, Georgina, V; Hamid, Omid; Garon, Edward B.; Herbst, Roy S.; Andre, Thierry; Armand, Philippe; Bajorin, Dean; Bellmunt, Joaquim; Burtness, Barbara; Choueiri, Toni K.; Cohen, Ezra E. W.; Diaz Jr, Luis A.; Shitara, Kohei; Kulkarni, Girish; McDermott, David; Shah, Manish; Tabernero, Josep; Vogel, Arndt; Zinzani, Pier Luigi; Jafari, Niusha; Birdu, Steven; Snyderu, Ellen; Gause, Christine; Braccou, Oswaldo L.; Pietanza, M. Catherine; Gruberu, Todd; Ribas, Antoni

Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort Beztifan治疗晚期实体瘤的I期LITESPARK-001研究: 在透明细胞肾细胞癌队列中延长41个月的随访

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-01-01

PREAI

Jonasch, Eric; Bauer, Todd M.; Papadopoulos, Kyriakos P.; Plimack, Elizabeth R.; Merchan, Jaime R.; Mcdermott, David F.; Michaelson, M. Dror; Appleman, Leonard J.; Roy, Ananya; Perini, Rodolfo F.; Liu, Yanfang; Choueiri, Toni K.

研究方向